DIRUI(SZ:300396) Zheng Quan Shi Bao Wang·2025-04-08 11:59Core Viewpoint - Dier Medical reported a significant decline in revenue and net profit for 2024, attributed to macroeconomic factors, industry adjustments, and changes in procurement policies, while outlining strategies for sustainable development and cash flow management [1][2]. Group 1: Financial Performance - In 2024, Dier Medical achieved revenue of 1.218 billion yuan, a year-on-year decrease of 11.63% [1] - The net profit for 2024 was 142 million yuan, down 48.5% year-on-year [1] - The quarterly revenue breakdown for 2024 was 663 million yuan in Q1, 216 million yuan in Q2, 297 million yuan in Q3, and 42.36 million yuan in Q4 [1] Group 2: Business Strategy and Adjustments - The company adjusted its sales strategy in Q4 2024 in response to industry changes, impacting that quarter's revenue [2] - Dier Medical is focusing on improving profitability, enhancing market competitiveness, and optimizing resource allocation to ensure long-term stability [2] - Measures to address cash flow pressures include dynamic tracking of accounts receivable and optimizing supplier payment terms [2] Group 3: International Market and Product Development - Dier Medical's direct exports to the U.S. are minimal, with an estimated revenue of about 150,000 USD in 2024 [3] - The company has established a presence in markets such as Russia, Latin America, Southeast Asia, and the Middle East, with a diverse product range [3] - The integration of AI algorithms for diagnostic support aims to enhance the efficiency and accuracy of clinical decision-making [3]